Physician profile
Michael Monahan
NPI 1447238480
$3,206.04
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $310 · 2021: $309 · 2022: $608 · 2023: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418 · Education: $20.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.85 |
| Education | $20.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $434.63 | 2019-2023 | Jynarque |
| Alexion Pharmaceuticals, INC. | $338.34 | 2019-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $298.94 | 2019-2023 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $227.08 | 2019-2023 | Krystexxa |
| Amgen INC. | $207.74 | 2019-2023 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $202.44 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $191.39 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $178.29 | 2021-2022 | |
| Glaxosmithkline, LLC. | $161.23 | 2022-2023 | Benlysta |
| Akebia Therapeutics INC | $153.45 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $126.51 | 2019-2020 | |
| Genzyme Corporation | $117.47 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $100.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.14 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $68.80 | 2022-2023 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $54.65 | 2019 | |
| Nuwellis, INC. | $44.66 | 2019 | |
| Shire North American Group INC | $36.86 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.69 | 2023 | Jynarque |
| Ani Pharmaceuticals, INC. | $22.77 | 2022 | |
| Bard Peripheral Vascular, INC. | $21.20 | 2019 | |
| Travere Therapeutics, INC. | $20.93 | 2022 | |
| Opko Pharmaceuticals, LLC | $20.26 | 2023 | Rayaldee |
| Calliditas Therapeutics US INC. | $19.96 | 2022 | |
| Nxstage Medical, INC. | $18.47 | 2019 | |
| Daiichi Sankyo INC. | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Monahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.